{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-002135","form_type":"8-K","ticker":"VSTM","cik":"0001526119","company_name":"Verastem, Inc.","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.321852+00:00","generated_at":"2026-05-16T11:12:16.149448+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Verastem provides pipeline update; Q3 net product revenue $11.2M; cash runway into 1H2027","bullets":["AVMAPKI FAKZYNJA CO-PACK launch momentum: $11.2M net product revenue Q3 2025, 133 prescribers.","Phase 3 RAMP 301 trial fully accrued; topline PFS data expected mid-2027.","VS-7375 KRAS G12D inhibitor: cleared 900 mg QD dose no DLTs; FDA FTD in PDAC.","Pipeline milestones: RAMP 205 update 1H2026; VS-7375 monotherapy expansion cohorts 1H2026.","Extended cash runway into 1H2027 via Oberland debt refinancing and equity investment."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-002135","json":"https://secwatch.observer/filing/0001104659-26-002135.json","markdown":"https://secwatch.observer/filing/0001104659-26-002135.md","text":"https://secwatch.observer/filing/0001104659-26-002135.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1526119/000110465926002135/0001104659-26-002135-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1526119/000110465926002135/tm262531d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:12:16.149448+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}